FDA Panel Votes for IR Opioid but Without Abuse LabelingFDA Panel Votes for IR Opioid but Without Abuse Labeling

Despite the drug company's presentations, FDA advisory committee members didn't find enough evidence to recommend abuse-deterrent labeling for the new immediate-release product. Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news